Connecting Skin and Gut in Dermatitis Herpetiformis: Insights from Gluten Challenge Transcriptomics
DOI:
https://doi.org/10.2340/actadv.v106.adv-2026-0792Keywords:
dermatitis herpetiformis, transcriptome, autoimmune diseaseAbstract
Dermatitis herpetiformis (DH) is a dietary gluten -induced autoimmune blistering skin disease. It is hypothesized to be initiated by a small intestinal mucosal immune response. Gluten-free diet (GFD) is the primary treatment for DHdermatitis herpetiformis and effectively resolves skin lesions. Previous studies show that after gluten reintroduction, peripheral cell responses are detectable already in six6 days, and most patients relapse clinically within months. The relapse presentation may differ between patients, with some experiencing both rash and small intestinal mucosal damage and some only one of these. Here, RNA transcriptomics were utilized to characterize temporal systemic and small intestinal mucosal responses to gluten in DH,dermatitis herpetiformis and to identify transcriptomic profiles specific for rash or villous atrophy as relapse presentations. The cohort consisted of 19 DHdermatitis herpetiformis patients on GFDgluten-free diet who underwent a gluten challenge. Gluten challenge elicited pronounced gene expression changes related to inflammation in the small intestine. In patients relapsing with rash, DOCK8 expression was significantly upregulated, while IL10RB was downregulated at end of follow-up. These patients also had significantly increased frequency of intraepithelial lymphocytes. Our findings show that prolonged gluten exposure alters duodenal transcriptomic profiles considerably. Moreover, patterns related to rash could be detected and present interesting candidates for future studies.
Downloads
References
Görög A, Antiga E, Caproni M, Cianchini G, De D, Dmochowski M, et al. S2k guidelines (consensus statement) for diagnosis and therapy of dermatitis herpetiformis initiated by the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol 2021; 35: 1251–1277. DOI: https://doi.org/10.1111/jdv.17183
Sárdy M, Kárpáti S, Merkl B, Paulsson M, Smyth N. Epidermal transglutaminase (TGase 3) is the autoantigen of dermatitis herpetiformis. J Exp Med 2002; 195: 747–757. DOI: https://doi.org/10.1084/jem.20011299
Reunala T, Hervonen K, Salmi T. Dermatitis herpetiformis: an update on diagnosis and management. Am J Clin Dermatol 2021; 22: 329–338. DOI: https://doi.org/10.1007/s40257-020-00584-2
Sankari H, Hietikko M, Kurppa K, Kaukinen K, Mansikka E, Huhtala H, et al. Intestinal TG3- and TG2-specific plasma cell responses in dermatitis herpetiformis patients undergoing a gluten challenge. Nutrients 2020; 12: 467. DOI: https://doi.org/10.3390/nu12020467
Das S, Stamnaes J, Kemppainen E, Hervonen K, Lundin KEA, Parmar N, et al. Separate gut plasma cell populations produce auto-antibodies against transglutaminase 2 and transglutaminase 3 in dermatitis herpetiformis. Adv Sci 2023; 10. DOI: https://doi.org/10.1002/advs.202300401
Ludvigsson JF, Leffler DA, Bai JC, Biagi F, Fasano A, Green PHR, et al. The Oslo definitions for coeliac disease and related terms. Gut 2013; 62: 43–52. DOI: https://doi.org/10.1136/gutjnl-2011-301346
Kemppainen E, Salmi T, Lindfors K. Missing insight into T and B cell responses in dermatitis herpetiformis. Front Immunol 2021; 12: 657280. DOI: https://doi.org/10.3389/fimmu.2021.657280
Bardella MT, Fredella C, Trovato C, Ermacora E, Cavalli R, Saladino V, et al. Long-term remission in patients with dermatitis herpetiformis on a normal diet. Br J Dermatol 2003; 149: 968–971. DOI: https://doi.org/10.1111/j.1365-2133.2003.05579.x
Kósnai I, Kárpati S, Savilahti E, Verkasalo M, Bucsky P, Török E. Gluten challenge in children with dermatitis herpetiformis: a clinical, morphological and immunohistological study. Gut 1986; 27: 1464–1470. DOI: https://doi.org/10.1136/gut.27.12.1464
Lancaster-Smith M, Kumar PJ, Dawson AM. The cellular infiltrate of the jejunum in adult coeliac disease and dermatitis herpetiformis following the reintroduction of dietary gluten. Gut 1975; 16: 683–688. DOI: https://doi.org/10.1136/gut.16.9.683
Leonard J, Haffenden G, Tucker W, Unsworth J, Swain F, McMinn R, et al. Gluten challenge in dermatitis herpetiformis. N Engl J Med 1983; 308: 816–819. DOI: https://doi.org/10.1056/NEJM198304073081406
Mansikka E, Hervonen K, Kaukinen K, Ilus T, Oksanen P, Lindfors K, et al. Gluten challenge induces skin and small bowel relapse in long-term gluten-free diet-treated dermatitis herpetiformis. J Invest Dermatol 2019; 139: 2108–2114. DOI: https://doi.org/10.1016/j.jid.2019.03.1150
Kalliokoski S, Mansikka E, de Kauwe A, Huhtala H, Saavalainen P, Kurppa K, et al. Gliadin-induced ex vivo T-cell response in dermatitis herpetiformis: a predictor of clinical relapse on gluten challenge? J Invest Dermatol 2020; 140: 1867–1869. DOI: https://doi.org/10.1016/j.jid.2019.12.038
Risnes LF, Chlubnová M, Magistrelli E, Kemppainen E, Hervonen K, Mansikka E, et al. Phenotypic analysis of disease-relevant T cells in dermatitis herpetiformis. J Invest Dermatol 2023; 143: 163–166. DOI: https://doi.org/10.1016/j.jid.2022.07.007
Yohannes DA, de Kauwe A, Kaukinen K, Kurppa K, Mäki M, Anderson RP, et al. Effects of in vivo gluten challenge on PBMC gene expression profiles in diet-treated celiac disease. Front Immunol 2020; 11: 594243. DOI: https://doi.org/10.3389/fimmu.2020.594243
Dotsenko V, Oittinen M, Taavela J, Popp A, Peräaho M, Staff S, et al. Genome-wide transcriptomic analysis of intestinal mucosa in celiac disease patients on a gluten-free diet and postgluten challenge. Cell Mol Gastroenterol Hepatol 2021; 11: 13–32. DOI: https://doi.org/10.1016/j.jcmgh.2020.07.010
Anderson RP, Degano P, Godkin AJ, Jewell DP, Hill AVS. In vivo antigen challenge in celiac disease identifies a single transglutaminase-modified peptide as the dominant A-gliadin T-cell epitope. Nat Med 2000; 6: 337–342. DOI: https://doi.org/10.1038/73200
Macosko EZ, Basu A, Satija R, Nemesh J, Shekhar K, Goldman M, et al. Highly parallel genome-wide expression profiling of individual cells using nanoliter droplets. Cell 2015; 161: 1202–1214. DOI: https://doi.org/10.1016/j.cell.2015.05.002
Freitag TL, Podojil JR, Pearson RM, Fokta FJ, Sahl C, Messing M, et al. Gliadin nanoparticles induce immune tolerance to gliadin in mouse models of celiac disease. Gastroenterology 2020; 158: 1667–1681. DOI: https://doi.org/10.1053/j.gastro.2020.01.045
Vuorela A, Freitag TL, Leskinen K, Pessa H, Härkönen T, Stracenski I, et al. Enhanced influenza A H1N1 T cell epitope recognition and cross-reactivity to protein-O-mannosyltransferase 1 in Pandemrix-associated narcolepsy type 1. Nat Commun 2021; 12: 2283. DOI: https://doi.org/10.1038/s41467-021-22637-8
Dolcino M, Cozzani E, Riva S, Parodi A, Tinazzi E, Lunardi C, et al. Gene expression profiling in dermatitis herpetiformis skin lesions. Clin Dev Immunol 2012; 2012: 198956. DOI: https://doi.org/10.1155/2012/198956
Torinsson Naluai Å, Sabbag S, Abrahamsson S, Gudjónsdóttir AH, Arnell H, Agardh D. Whole genome transcriptional analysis of intestinal biopsies and blood cells indicate genes involved in antioxidant defense systems, amino acid metabolism and antigen presentation in the pathogenesis of celiac disease. BMC Med 2025; 23: 507. DOI: https://doi.org/10.1186/s12916-025-04261-1
Ramírez-Sánchez AD, Zühlke S, Aguirre-Gamboa R, Vochteloo M, Franke L, Lundin KEA, et al. Transcriptomics and eQTLs reveal inflammatory heterogeneity in the duodenal lining in coeliac disease. Genes Immun 2025; 26: 519–530. DOI: https://doi.org/10.1038/s41435-025-00356-0
Dotsenko V, Tewes B, Hils M, Pasternack R, Isola J, Taavela J, et al. Transcriptomic analysis of intestine following administration of a transglutaminase 2 inhibitor to prevent gluten-induced intestinal damage in celiac disease. Nat Immunol 2024; 25: 1218–1230. DOI: https://doi.org/10.1038/s41590-024-01867-0
Stamnaes J, Stray D, Stensland M, Sarna VK, Nyman TA, Lundin KEA, et al. In well-treated celiac patients low-level mucosal inflammation predicts response to 14-day gluten challenge. Adv Sci 2021; 8: 2003526. DOI: https://doi.org/10.1002/advs.202003526
Glocker EO, Kotlarz D, Boztug K, Gertz EM, Schäffer AA, Noyan F, et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med 2009; 361: 2033–2045. DOI: https://doi.org/10.1056/NEJMoa0907206
Kotlarz D, Beier R, Murugan D, Diestelhorst J, Jensen O, Boztug K, et al. Loss of interleukin-10 signaling and infantile inflammatory bowel disease: implications for diagnosis and therapy. Gastroenterology 2012; 143: 347–355. DOI: https://doi.org/10.1053/j.gastro.2012.04.045
Zheng C, Huang Y, Hu W, Shi J, Ye Z, Qian X, et al. Phenotypic characterization of very early-onset inflammatory bowel disease with interleukin-10 signaling deficiency: based on a large cohort study. Inflamm Bowel Dis 2019; 25: 756–766. DOI: https://doi.org/10.1093/ibd/izy289
Ouyang W, O’Garra A. IL-10 family cytokines IL-10 and IL-22: from basic science to clinical translation. Immunity 2019; 50: 871–891. DOI: https://doi.org/10.1016/j.immuni.2019.03.020
Biggs CM, Keles S, Chatila TA. DOCK8 deficiency: insights into pathophysiology, clinical features and management. Clin Immunol 2017; 181: 75–82. DOI: https://doi.org/10.1016/j.clim.2017.06.003
Zhang B, Chen S, Yin X, McBride CD, Gertie JA, Yurieva M, et al. Metabolic fitness of IgA+ plasma cells in the gut requires DOCK8. Mucosal Immunol 2024; 17: 431–449. DOI: https://doi.org/10.1016/j.mucimm.2023.12.001
FitzPatrick MEB, Antanaviciute A, Dunstan M, Künnapuu K, Trzupek D, Provine NM, et al. Immune-epithelial-stromal networks define the cellular ecosystem of the small intestine in celiac disease. Nat Immunol 2025; 26: 947–962. DOI: https://doi.org/10.1038/s41590-025-02146-2
Atlasy N, Bujko A, Bækkevold ES, Brazda P, Janssen-Megens E, Lundin KEA, et al. Single cell transcriptomic analysis of the immune cell compartment in the human small intestine and in Celiac disease. Nat Commun 2022; 13: 4920. DOI: https://doi.org/10.1038/s41467-022-32691-5
Holtmeier W, Pfänder M, Zollner TM, Kaufmann R, Caspary WF. Distinct TCR delta repertoires are present in the cutaneous lesions and inflamed duodenum of patients with dermatitis herpetiformis. Exp Dermatol 2002; 11: 527–531. DOI: https://doi.org/10.1034/j.1600-0625.2002.110605.x
Additional Files
Published
How to Cite
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
